EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers

Laura Bender Somme, Christos Chouaid, Fabien Moinard-Butot, Jean-Baptiste Barbe-Richaud, Laurent Greillier, Roland Schott

BioDrugs · 2024

DOI: 10.1007/s40259-024-00660-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift BioDrugs, 2024. Verfasst von Laura Bender Somme und 5 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Department, Institut de Cancérologie Strasbourg, 17 avenue Albert Calmette, 67200, Strasbourg, France. l.bender@icans.eu. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Immunoconjugates, Lung Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-drug conjugates (ADCs) are an emerging class of therapeutics for lung cancer, and several are currently in development for this malignancy. The structure of these molecules is based on an antibody that targets a protein on the lung cancer cell surface and a cytotoxic payload attached by a linker. Many protein targets, including TROP2, c-MET, CEACAM5, HER2, and HER3 have been identified. In metastatic non-small cell lung carcinoma (NSCLC) without alterations in oncogenic drivers, platinum-based chemotherapy and immune checkpoint inhibitors (ICIs) targeting the programmed death-1/programmed death-ligand 1 (PD1/PDL1) interaction are the standard first-line treatments. In patients with EGFR-mutated or ALK-rearranged NSCLC, tyrosine kinase inhibitors (TKIs) are recommended. However, although the prognosis of patients with metastatic NSCLC differs between such with and without alterations in oncogenic drivers, most patients eventually experience disease progression. A novel therapeutic class is needed in routine practice to overcome the mechanisms of resistance to ICIs and EGFR/ALK TKIs. Several ADCs have already been approved for other cancers, such as breast cancer and urothelial carcinoma. This review summarizes the knowledge about the efficacy and tolerance profiles of ADCs targeting TROP2, HER2, HER3, CEACAM5 and c-MET in metastatic NSCLC with and without alterations in oncogenic drivers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungImmunoconjugatesLung NeoplasmsHumansCell Adhesion MoleculesAntineoplastic AgentsProto-Oncogene Proteins c-metMolecular Targeted Therapy

Substanzen

ImmunoconjugatesCell Adhesion MoleculesAntineoplastic AgentsProto-Oncogene Proteins c-met

Autor:innen und Institutionen

  • Oncology Department, Institut de Cancérologie Strasbourg, 17 avenue Albert Calmette, 67200, Strasbourg, France. l.bender@icans.eu.
  • Pneumology Department, Hôpital Intercommunal de Créteil, 40 avenue de Verdun, 94010, Creteil, France.
  • Oncology Department, Institut de Cancérologie Strasbourg, 17 avenue Albert Calmette, 67200, Strasbourg, France.
  • Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique-Hôpitaux de Marseille, Aix Marseille University, Chemin des Bourrely, 13915, Marseille, France.

Zitieren

APA

Somme, L. B., Chouaid, C., Moinard-Butot, F., Barbe-Richaud, J. B., Greillier, L., & Schott, R. (2024). Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers. BioDrugs. https://doi.org/10.1007/s40259-024-00660-7

Vancouver

Somme LB, Chouaid C, Moinard-Butot F, Barbe-Richaud JB, Greillier L, Schott R. Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers. BioDrugs. 2024. doi:10.1007/s40259-024-00660-7

BibTeX
@article{Somme2024,
  author = {Somme, Laura Bender and Chouaid, Christos and Moinard-Butot, Fabien and Barbe-Richaud, Jean-Baptiste and Greillier, Laurent and Schott, Roland},
  title = {Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers},
  journal = {BioDrugs},
  year = {2024},
  doi = {10.1007/s40259-024-00660-7}
}
Kostenlos starten →